CURX
Curanex Pharmaceuticals Inc
Price Chart
Latest Quote
$0.28
-0.05 (-16.42%)
Current Price
| Previous Close | $0.34 |
| Open | $0.34 |
| Day High | $0.34 |
| Day Low | $0.28 |
| Volume | 138,885 |
Stock Information
| Shares Outstanding | 28.34M |
| Total Debt | $476K |
| Cash Equivalents | $109K |
| Net Income | $-435K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.94M |
| EPS (TTM) | $-0.02 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $19.13M |
| Income | $-435K |
| Book/sh | $0.01 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 1.43 |
| Current Ratio | 9.37 |
| Debt/Eq | 155.99 |
Returns & Margins
| ROA | -30.03% |
| ROE | -85.25% |
Ownership
| Insider Ownership | 67.81% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 21.54 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.33 |
| SMA50 | $0.37 |
| SMA200 | $0.83 |
| RSI | 37.90 |
| ATR | 0.0314 |
| Shares Float | 8.91M |
| Short Float | 0.67% |
| Short Ratio | 0.03 |
| Rel Volume | 1.94 |
Performance History
| Week | -16.91% |
| Month | -7.28% |
| Quarter | -34.12% |
| 6 Months | -31.03% |
| YTD | -23.91% |
| 10 Years | -93.03% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.28 | 163,500 |
| 2026-06-17 | $0.34 | 50,200 |
| 2026-06-16 | $0.32 | 85,000 |
| 2026-06-15 | $0.34 | 127,300 |
| 2026-06-12 | $0.32 | 140,500 |
| 2026-06-11 | $0.34 | 170,400 |
| 2026-06-10 | $0.33 | 127,200 |
| 2026-06-09 | $0.31 | 60,200 |
| 2026-06-08 | $0.31 | 52,600 |
| 2026-06-05 | $0.30 | 111,400 |
| 2026-06-04 | $0.33 | 62,900 |
| 2026-06-03 | $0.33 | 40,700 |
| 2026-06-02 | $0.34 | 115,900 |
| 2026-06-01 | $0.33 | 36,700 |
| 2026-05-29 | $0.33 | 71,100 |
| 2026-05-28 | $0.34 | 30,100 |
| 2026-05-27 | $0.34 | 115,000 |
| 2026-05-26 | $0.33 | 31,200 |
| 2026-05-22 | $0.33 | 46,900 |
| 2026-05-21 | $0.33 | 47,800 |
| 2026-05-20 | $0.33 | 123,800 |
| 2026-05-19 | $0.30 | 21,000 |
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on CURX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $26,000 |
| Operating Revenue | $0 | $0 | $0 | $26,000 |
| Reconciled Cost Of Revenue | - | - | $0 | $21,571 |
| Cost Of Revenue | - | - | $0 | $21,571 |
| Expenses | ||||
| Interest Expense | $8,537 | $0 | - | - |
| Total Expenses | $4,239,076 | $290,386 | $19,298 | $46,233 |
| Other Income Expense | $22,507 | $-71,120 | $100 | - |
| Other Non Operating Income Expenses | $22,507 | $3,556 | $100 | - |
| Net Non Operating Interest Income Expense | $-8,537 | $0 | - | - |
| Interest Expense Non Operating | $8,537 | $0 | - | - |
| Operating Expense | $4,239,076 | $290,386 | $19,298 | $24,662 |
| General And Administrative Expense | $1,253,203 | $290,386 | $19,298 | $24,662 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Net Interest Income | $-8,537 | $0 | - | - |
| Normalized Income | $-4,225,106 | $-286,830 | $-19,198 | $-20,233 |
| Net Income From Continuing And Discontinued Operation | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Total Operating Income As Reported | $-4,239,076 | $-365,062 | $-19,298 | $-20,233 |
| Net Income Common Stockholders | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Net Income | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Net Income Including Noncontrolling Interests | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Net Income Continuous Operations | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Pretax Income | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Special Income Charges | $0 | $-74,676 | $0 | - |
| Operating Income | $-4,239,076 | $-290,386 | $-19,298 | $-20,233 |
| Gross Profit | - | - | $0 | $4,429 |
| Per Share | ||||
| Diluted EPS | $-0.17 | $-0.01 | $-0.00 | $-0.02 |
| Basic EPS | $-0.17 | $-0.01 | $-0.00 | $-0.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,137,173 | $-286,830 | $-17,483 | $925 |
| Total Unusual Items | $0 | $-74,676 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-74,676 | $0 | - |
| Reconciled Depreciation | $79,396 | $0 | $1,815 | $21,158 |
| EBITDA (Bullshit earnings) | $-4,137,173 | $-361,506 | $-17,483 | $925 |
| EBIT | $-4,216,569 | $-361,506 | $-19,298 | $-20,233 |
| Diluted Average Shares | $25,497,328 | $42,000,000 | $42,000,000 | $42,000,000 |
| Basic Average Shares | $25,497,328 | $27,750,000 | $42,000,000 | $42,000,000 |
| Diluted NI Availto Com Stockholders | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Impairment Of Capital Assets | $0 | $74,676 | $0 | - |
| Research And Development | $2,985,873 | $0 | - | - |
| Selling General And Administration | $1,253,203 | $290,386 | $19,298 | $24,662 |
| Other Gand A | $1,253,203 | $290,386 | $19,298 | $24,662 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,219,084 | $503,360 | $60,090 | $10,232 |
| Total Assets | $11,580,124 | $517,935 | $74,366 | $10,232 |
| Total Non Current Assets | $352,616 | $0 | $0 | $0 |
| Current Assets | $11,227,508 | $517,935 | $74,366 | $10,232 |
| Current Deferred Assets | $0 | $367,865 | $0 | - |
| Prepaid Assets | $6,254,374 | $1,179 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $4,973,134 | $148,891 | $74,366 | $2,430 |
| Cash And Cash Equivalents | $4,973,134 | $148,891 | $74,366 | $2,430 |
| Cash Financial | $4,973,134 | $148,891 | $74,366 | $2,430 |
| Other Current Assets | - | $367,865 | - | $1,815 |
| Inventory | - | - | $0 | $2,987 |
| Receivables | - | - | $0 | $3,000 |
| Debt | ||||
| Total Debt | $346,699 | $0 | - | - |
| Long Term Debt And Capital Lease Obligation | $224,010 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $122,689 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $361,040 | $14,575 | $14,276 | $0 |
| Total Non Current Liabilities Net Minority Interest | $224,010 | $0 | $0 | $0 |
| Current Liabilities | $137,030 | $14,575 | $14,276 | $0 |
| Payables And Accrued Expenses | $14,341 | $14,575 | $14,276 | $0 |
| Payables | $2,451 | $5,025 | $600 | - |
| Total Tax Payable | $25 | $25 | $600 | $0 |
| Accounts Payable | $2,426 | $5,000 | $0 | - |
| Equity | ||||
| Common Stock Equity | $11,218,984 | $503,260 | $60,090 | $10,232 |
| Preferred Stock Equity | $100 | $100 | - | - |
| Total Equity Gross Minority Interest | $11,219,084 | $503,360 | $60,090 | $10,232 |
| Stockholders Equity | $11,219,084 | $503,360 | $60,090 | $10,232 |
| Retained Earnings | $-4,847,555 | $-622,449 | $-260,943 | $-241,745 |
| Other Equity Interest | - | $200,000 | $200,000 | $200,000 |
| Other | ||||
| Ordinary Shares Number | $28,340,812 | $27,750,000 | $27,750,000 | $27,750,000 |
| Share Issued | $28,340,812 | $27,750,000 | $27,750,000 | $27,750,000 |
| Tangible Book Value | $11,218,984 | $503,260 | $60,090 | $10,232 |
| Invested Capital | $11,218,984 | $503,260 | $60,090 | $10,232 |
| Working Capital | $11,090,478 | $503,360 | $60,090 | $10,232 |
| Capital Lease Obligations | $346,699 | $0 | - | - |
| Total Capitalization | $11,219,084 | $503,360 | $60,090 | $10,232 |
| Additional Paid In Capital | $16,063,705 | $923,309 | $120,973 | $51,877 |
| Capital Stock | $2,934 | $2,500 | $60 | $100 |
| Common Stock | $2,834 | $2,400 | $60 | $100 |
| Preferred Stock | $100 | $100 | $0 | $0 |
| Long Term Capital Lease Obligation | $224,010 | $0 | - | - |
| Current Capital Lease Obligation | $122,689 | $0 | - | - |
| Current Accrued Expenses | $11,890 | $9,550 | $13,676 | $0 |
| Net PPE | $352,616 | $0 | - | - |
| Gross PPE | $352,616 | $0 | - | - |
| Other Properties | $352,616 | - | - | - |
| Duefrom Related Parties Current | - | - | $0 | $3,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,484,452 | $-555,575 | $-120 | $3,336 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,484,452 | $-555,575 | $-120 | $3,336 |
| Cash Flow From Continuing Operating Activities | $-10,484,452 | $-555,575 | $-120 | $3,336 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $15,655,192 | $630,100 | $69,056 | $0 |
| Financing Cash Flow | $15,308,695 | $630,100 | $72,056 | $-3,000 |
| Cash Flow From Continuing Financing Activities | $15,308,695 | $630,100 | $72,056 | $-3,000 |
| Net Other Financing Charges | $-346,497 | - | $3,000 | $-3,000 |
| Net Preferred Stock Issuance | $0 | $100 | $0 | - |
| Preferred Stock Issuance | $0 | $100 | $0 | - |
| Net Common Stock Issuance | $15,655,192 | $630,000 | $69,056 | $0 |
| Common Stock Issuance | $15,655,192 | $630,000 | $69,056 | $0 |
| Other | ||||
| End Cash Position | $4,973,134 | $148,891 | $74,366 | $2,430 |
| Beginning Cash Position | $148,891 | $74,366 | $2,430 | $2,094 |
| Changes In Cash | $4,824,243 | $74,525 | $71,936 | $336 |
| Change In Working Capital | $-6,338,742 | $-268,745 | $17,263 | $2,411 |
| Change In Other Current Liabilities | $-85,210 | $0 | $0 | $-19,160 |
| Change In Other Current Assets | $0 | $-267,865 | $0 | - |
| Change In Payables And Accrued Expense | $-234 | $299 | $14,276 | $0 |
| Change In Accrued Expense | $2,340 | $-4,701 | $14,276 | $0 |
| Change In Payable | $-2,574 | $5,000 | - | - |
| Change In Account Payable | $-2,574 | $5,000 | $0 | - |
| Change In Prepaid Assets | $-6,253,298 | $-1,179 | $0 | - |
| Asset Impairment Charge | $0 | $74,676 | - | - |
| Depreciation Amortization Depletion | $79,396 | $0 | $1,815 | $21,158 |
| Depreciation And Amortization | $79,396 | $0 | $1,815 | $21,158 |
| Depreciation | $79,396 | $0 | $1,815 | $21,158 |
| Net Income From Continuing Operations | $-4,225,106 | $-361,506 | $-19,198 | $-20,233 |
| Change In Inventory | - | $0 | $2,987 | $21,571 |
Fetched: 2026-06-16